Overview

Gender

male

Investor Type

Investment Partner

Fund principal for the Mercia Technology Seed Fund. Mark has a PhD from King's College (University of London) and an MBA from Warwick Business School. Prior to joining the fund, Mark was a research fellow at the Department of Pharmacology (University of Oxford), played leading roles within Isis Innovation (the technology transfer arm of the University of Oxford, ranked as the premier technology transfer office in the UK) and was VP Corporate Development at Oxxon Therapeutics Inc (before its sale to Oxford BioMedica Plc). Mark benefits from in excess of 15 years experience from the commercialisation of life science opportunities in the biotech, niche pharma, medtech and diagnostics fields.